Public versus Private Drug Insurance and Outcomes of Patients Requiring Biologic Therapies for Inflammatory Bowel Disease

Table 3

Results of the Cox regression analysis of type of drug insurance coverage and time to first anti-TNF dose.

Characteristic	Hazard ratio	95% CI
Public drug coverage	0.67	0.45–0.95
Age	1.00	0.98–1.03
Age at IBD diagnosis	1.00	0.98–1.03
Female gender	1.10	0.78–1.56
Crohn’s disease	1.46	1.00–2.12
Immunomodulator use	1.16	0.82–1.65
Steroid dependent or refractory disease	1.02	0.74–1.41
IBD of aggressive behaviour	0.81	0.55–1.18
Copay scheme use	0.74	0.37–1.48